Vaxnewmo, LLC

Publicly observed

Saint Louis, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

Item	Value	Source	Status
Country	US	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
City / locality	Saint Louis	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
Name	Vaxnewmo, LLC	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
UEI (U.S. federal entity ID)	HVUWF1K69W37	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed

Grant15 Jul 2022Publicly observed
NIH SBIR/STTR award: A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant15 Jul 2022Publicly observed
NIH SBIR/STTR award: A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections
USD 999,717.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant1 Jan 2022Publicly observed
NIH SBIR/STTR award: A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections
USD 999,022.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant1 Jan 2022Publicly observed
NIH SBIR/STTR award: A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant12 Mar 2019Publicly observed
NIH SBIR/STTR award: Development of a Group B Streptococcus bioconjugate vaccine
USD 995,682.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.